STEMA_cg is built on data-driven Strategies optimized to highly technical & regulated environments. We help you go to market fast & informed.

STEMA_cg is a boutique advisory firm specializing in data-driven go-to-market strategy and insights for product development and commercialization in life sciences and healthcare.

We combine proven real-world experience building and commercializing high-growth products, with data-driven decision-making using open-source intelligence (OSINT), alternative data, and machine learning to deliver actionable insights and results.

We offer a range of tailored services designed to meet your company needs (e.g. targeted market analysis, planning and executing product launches, transformations, etc.). We partner with leaders in early-stage and small and medium-sized enterprises (SMEs) to solve complex business problems and create value for their shareholders and customers.

Visit The Lab to learn more about our philosophy and frameworks.

Mida Pezeshkian, PhD

Founder & Principal

Mida Pezeshkian is the Founder & Principal of STEMA_cg, which helps life sciences and healthcare organizations develop and commercialize competitive products. Mida combines advanced analytics and real-world experience to identify business strategy, plan go-to-market, and execute fast commercialization.

Mida has leadership experience in product and strategy across genomics, clinical diagnostics laboratory, and digital health, where she created and scaled engineering, product, marketing, and data science teams to build novel solutions.

As a former scientist, Mida couples her business-tailored scientific method with creative problem solving to develop novel solutions that create value for her clients.

Career Highlights

  • Led the development of an award-winning electronic health record system with integrated artificial intelligence and machine learning (AI/ML) workflows to improve clinical decision making and operational efficiency.

  • Launched and scaled Michigan's second COVID-19 testing laboratory in April 2020, implementing creative automation and supply management workflows to deliver consistent testing output during the pandemic crisis, while launching >25 test lines in molecular, toxicology, and blood in 6 months development time.

  • Spearheaded change management and commercialization of novel genomics products to position a VC-backed startup for acquisition by a Danaher company.

  • Discovered the role of an inflammatory positive feedback loop contributing to chemoresistance and relapse in Acute Myeloid Leukemia (AML).

  • Patented a novel biosensor to non-invasively detect cell-cell interaction to identify disease stage, treatment plan, and relapse.